Who is sponsoring NCT06775873?

NCT06775873 is sponsored by Tongji University.

What drugs are being tested in NCT06775873?

Interventions in NCT06775873: Modified diaphragmatic plication.

What condition does NCT06775873 study?

NCT06775873 studies Phrenic Nerve Injury.

Is NCT06775873 still recruiting?

NCT06775873 is currently completed. Last updated 15 January 2025.

Last reviewed 2025-01-15 · How we verify

NCT06775873

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Modified Diaphragmatic Plication Rectifies Dyspnea

Completed Last updated 15 January 2025

What this trial tests

trial testing Modified diaphragmatic plication in Phrenic Nerve Injury in 50 participants. Completed in 1 June 2024.

Timeline

1 February 2023

Primary endpoint
1 May 2023

1 June 2024

Quick facts

Lead sponsor	Tongji University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	50
Start date	1 February 2023
Primary completion	1 May 2023
Estimated completion	1 June 2024
Sites	1 location across China

Drugs / interventions tested

Modified diaphragmatic plication

Conditions studied

Phrenic Nerve Injury — all drugs for Phrenic Nerve Injury →

Sponsor

Tongji University

Who can join

Adults 18 to 70, any sex, with Phrenic Nerve Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Traditional diaphragmatic plication (DP) surgery is employed to ameliorate respiratory function in patients with diaphragmatic paralysis, which is rather complicated. This study introduces a modified method of DP. The efficacy of modified diaphragmatic plication (MDP) in preventing, treating, and relieving dyspnea in patients with phrenic nerve resection or injury due to extensive surgical intervention or local tumor invasion will be evaluated.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Tongji University trials

Trials by the same sponsor.

NCT07361237 — A Phase l Clinical Study to Evalute the Safety,Tolerability,Pharmacokinetic Characteristics,and Preliminary Anti-tumor E · Phase 1 · recruiting
NCT07208123 — Mechanistic Studies of Chronic COPD Using Single-Cell Sequencing and Single-Cell Spatial Transcriptomics · not yet recruiting
NCT07047859 — Clinical Investigation of Sympathetic Nerve Width Measurement in Thoracoscopic Sympathectomy · not yet recruiting
NCT07074704 — tACS to Improve Negative Symptoms & Cognition in Long-term Hospitalized Schizophrenia Patients. · NA · enrolling by invitation
NCT06740188 — Trazodone on NREM Sleep Stage Ⅲ in Depressed Insomniac Co-morbid Patients · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06775873 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tongji University
Last refreshed: 15 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06775873.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing